Welcome to LookChem.com Sign In|Join Free
  • or
methyl 2-(4-((phenoxycarbonyl)amino)phenyl)acetate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

199729-04-9

Post Buying Request

199729-04-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

199729-04-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 199729-04-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,7,2 and 9 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 199729-04:
(8*1)+(7*9)+(6*9)+(5*7)+(4*2)+(3*9)+(2*0)+(1*4)=199
199 % 10 = 9
So 199729-04-9 is a valid CAS Registry Number.

199729-04-9Relevant academic research and scientific papers

A practical synthesis of ureas from phenyl carbamates

Thavonekham, Bounkham

, p. 1189 - 1194 (1997)

Using DMSO as solvent, a mild and efficient procedure for the synthesis of unsymmetrical N,N'-disubstituted ureas from phenyl carbamates is described. The carbamates are treated with a stoichiometric amount of amine at ambient temperature, generating the

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors

Suebsuwong, Chalada,Pinkas, Daniel M.,Ray, Soumya S.,Bufton, Joshua C.,Dai, Bing,Bullock, Alex N.,Degterev, Alexei,Cuny, Gregory D.

supporting information, p. 577 - 583 (2018/02/09)

Development of selective kinase inhibitors remains a challenge due to considerable amino acid sequence similarity among family members particularly in the ATP binding site. Targeting the activation loop might offer improved inhibitor selectivity since this region of kinases is less conserved. However, the strategy presents difficulties due to activation loop flexibility. Herein, we report the design of receptor-interacting protein kinase 2 (RIPK2) inhibitors based on pan-kinase inhibitor regorafenib that aim to engage basic activation loop residues Lys169 or Arg171. We report development of CSR35 that displayed >10-fold selective inhibition of RIPK2 versus VEGFR2, the target of regorafenib. A co-crystal structure of CSR35 with RIPK2 revealed a resolved activation loop with an ionic interaction between the carboxylic acid installed in the inhibitor and the side-chain of Lys169. Our data provides principle feasibility of developing activation loop targeting type II inhibitors as a complementary strategy for achieving improved selectivity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 199729-04-9